The Experts below are selected from a list of 7044 Experts worldwide ranked by ideXlab platform
David Navarro - One of the best experts on this subject based on the ideXlab platform.
-
performance of the QuantiFERON cytomegalovirus cmv assay for detection and estimation of the magnitude and functionality of the cmv specific gamma interferon producing cd8 t cell response in allogeneic stem cell transplant recipients
Clinical and Vaccine Immunology, 2012Co-Authors: María Ángeles Clari, Isabel Benet, Elisa Costa, María José Remigia, Dayana Bravo, Beatriz Munozcobo, Paula Amat, Carlos Solano, David NavarroAbstract:The performance of the QuantiFERON-cytomegalovirus (CMV) assay was compared to that of a flow cytometry intracellular cytokine staining (ICS) method for the detection of CMV-specific gamma interferon (IFN-γ)-producing CD8+ T-cell responses in allogeneic stem cell transplant (allo-SCT) recipients and for estimations of their magnitude and functionality. A total of 90 whole-blood specimens from 23 allo-SCT recipients was analyzed by both methods. Overall, the percentage of specimens that yielded concordant results by both methods was 68.8% (κ = 0.691; 95% confidence interval [CI], 0.548 to 0.835), and the sensitivity of the QuantiFERON-CMV assay for the detection of positive IFN-γ T-cell responses (>0.2 IU/ml), taking the ICS method as the reference, was 76.3%. The magnitude of IFN-γ-producing CD8+ T-cell responses to CMV-specific peptides measured with the QuantiFERON-CMV assay correlated significantly (σ = 0.695; P = 0.001]) CMV-specific CD8+ T-cell responses, as quantitated by ICS. In summary, the data indicated that the QuantiFERON-CMV assay is less sensitive than the ICS method for the detection of CMV-specific IFN-γ-producing CD8+ T-cell responses in the allo-SCT setting. Nevertheless, it allowed the estimation of the total and polyfunctional CMV-specific IFN-γ-producing CD8+ T-cell responses in specimens that tested positive by both methods.
-
Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8 + T-cell response in allogeneic stem cell transplant recipients
Clinical and Vaccine Immunology, 2012Co-Authors: María Ángeles Clari, Beatriz Munoz-cobo, Isabel Benet, Elisa Costa, María José Remigia, Dayana Bravo, Paula Amat, David NavarroAbstract:The performance of the QuantiFERON-cytomegalovirus (CMV) assay was compared to that of a flow cytometry intracellular cytokine staining (ICS) method for the detection of CMV-specific gamma interferon (IFN-γ)-producing CD8(+) T-cell responses in allogeneic stem cell transplant (allo-SCT) recipients and for estimations of their magnitude and functionality. A total of 90 whole-blood specimens from 23 allo-SCT recipients was analyzed by both methods. Overall, the percentage of specimens that yielded concordant results by both methods was 68.8% (κ = 0.691; 95% confidence interval [CI], 0.548 to 0.835), and the sensitivity of the QuantiFERON-CMV assay for the detection of positive IFN-γ T-cell responses (>0.2 IU/ml), taking the ICS method as the reference, was 76.3%. The magnitude of IFN-γ-producing CD8(+) T-cell responses to CMV-specific peptides measured with the QuantiFERON-CMV assay correlated significantly (σ = 0.695; P =
Naoyuki Miyashita - One of the best experts on this subject based on the ideXlab platform.
-
The positive response rate with QuantiFERON-TB GOLD In-Tube in patients with Mycobacterium avium complex
Kekkaku(Tuberculosis), 2012Co-Authors: Niro Okimoto, Fumiyo Nanba, Takeyuki Kurihara, Naoyuki MiyashitaAbstract:OBJECTIVE: We studied the positive response rate with QuantiFERON-TB GOLD In-Tube in patients with Mycobacterium avium complex disease. MATERIALS AND METHODS: We evaluated 62 subjects with M. avium complex disease. QuantiFERON-TB GOLD In-Tube was performed for all the subjects. The positive response rate with QuantiFERON-TB GOLD In-Tube and the history of pulmonary tuberculosis in patients who showed a positive response were evaluated. RESULTS: Seven patients (11.3%) showed a positive response with QuantiFERON-TB GOLD In-Tube. These patients were elderly (age, 72-87 years) and had a history of pulmonary tuberculosis. Eleven other patients with a history of pulmonary tuberculosis showed a negative response with QuantiFERON-TB GOLD In-Tube. CONCLUSION: Half or less than half of the elderly patients with M. avium complex disease and a history of pulmonary tuberculosis showed a positive response with QuantiFERON-TB GOLD In-Tube.
-
indeterminate results of QuantiFERON tb 2g test performed in routine clinical practice
European Respiratory Journal, 2009Co-Authors: Yoshihiro Kobashi, Keiji Mouri, Yasushi Obase, Tadaaki Sugiu, Naoyuki MiyashitaAbstract:The present authors assessed risk factors that can promote indeterminate results of QuantiFERON TB-2G (QFT-2G; Cellestis Ltd, Carnegie, Australia) tests. The subjects were 704 patients with suspected tuberculosis (TB) and latent TB infection between January 2005 and December 2007. The QFT-2G test and the tuberculin skin test (TST) were performed for all subjects. If the results of the QFT-2G test were indeterminate, the test was repeated within 1 month. In total, 72 (10.2%) patients showed indeterminate results on the QFT-2G test. Indeterminate results were due to positive control failure in 68 (88.9%) patients and negative control failure in four patients. The results of the TST were negative for 64 patients showing indeterminate results, the remaining eight patients showed a positive response to the TST. Indeterminate results were significantly associated with elderly and immunocompromised patients. Lymphocytopaenia and hypoalbuminaemia were significantly associated with indeterminate laboratory findings. When the QFT-2G test was repeated for all patients showing indeterminate results, 12 (16.7%) patients demonstrated determinate results on the subsequent test. Indeterminate results of the QuantiFERON TB-2G test under routine clinical practice are not infrequent. When scoring QuantiFERON TB-2G test results for elderly and immunocompromised patients, one must be careful because the possibility of obtaining determinate results may be low even if the test is repeated.
-
clinical evaluation of QuantiFERON tb 2g test for immunocompromised patients
European Respiratory Journal, 2007Co-Authors: Yoshihiro Kobashi, Keiji Mouri, Yasushi Obase, Minoru Fukuda, Naoyuki MiyashitaAbstract:The usefulness of the tuberculin skin test (TST) and the QuantiFERON TB-2G (QFT-TB) test were compared in immunocompromised patients. The subjects consisted of 252 immunocompromised patients who were clinically suspected of tuberculosis (TB) infection between April 2005 and December 2006. Regarding the underlying diseases, 74 subjects had malignant diseases, 72 were undergoing immunosuppressive treatment, 52 had diabetes mellitus, 50 had chronic renal failure and four had HIV infection. While the positive rate of the QFT-TB test for the diagnosis of TB infection (TB disease or latent TB infection) was 78.1%, that of TST for TB infection was 50.0%. The QFT-TB test was significantly better than TST. However, 32 (13%) patients had an indeterminate QFT-TB result. Indeterminate findings were significantly more frequent in patients receiving immunosuppressive treatment (28%), especially with lymphocytopaenia in the peripheral blood, than in those who had other underlying diseases. While TST-positive and QFT-TB test-negative results were recognised in immunocompromised patients with bacille Calmette–Guerin vaccination or nontuberculous mycobacterial disease, TST-negative and QFT-TB test-positive results were recognised in immunocompromised patients with a past history of TB infection. It was concluded that the QuantiFERON TB-2G test is a more useful diagnostic method for tuberculosis infection than tuberculin skin test for immunocompromised patients suspected of tuberculosis disease. However, because the results of the QuantiFERON TB-2G test show an indeterminate response for patients receiving immunosuppressive treatment, especially for those with lymphocytopaenia due to severe underlying diseases, care must be taken in the interpretation of the QuantiFERON TB-2G test for these patients.
María Ángeles Clari - One of the best experts on this subject based on the ideXlab platform.
-
performance of the QuantiFERON cytomegalovirus cmv assay for detection and estimation of the magnitude and functionality of the cmv specific gamma interferon producing cd8 t cell response in allogeneic stem cell transplant recipients
Clinical and Vaccine Immunology, 2012Co-Authors: María Ángeles Clari, Isabel Benet, Elisa Costa, María José Remigia, Dayana Bravo, Beatriz Munozcobo, Paula Amat, Carlos Solano, David NavarroAbstract:The performance of the QuantiFERON-cytomegalovirus (CMV) assay was compared to that of a flow cytometry intracellular cytokine staining (ICS) method for the detection of CMV-specific gamma interferon (IFN-γ)-producing CD8+ T-cell responses in allogeneic stem cell transplant (allo-SCT) recipients and for estimations of their magnitude and functionality. A total of 90 whole-blood specimens from 23 allo-SCT recipients was analyzed by both methods. Overall, the percentage of specimens that yielded concordant results by both methods was 68.8% (κ = 0.691; 95% confidence interval [CI], 0.548 to 0.835), and the sensitivity of the QuantiFERON-CMV assay for the detection of positive IFN-γ T-cell responses (>0.2 IU/ml), taking the ICS method as the reference, was 76.3%. The magnitude of IFN-γ-producing CD8+ T-cell responses to CMV-specific peptides measured with the QuantiFERON-CMV assay correlated significantly (σ = 0.695; P = 0.001]) CMV-specific CD8+ T-cell responses, as quantitated by ICS. In summary, the data indicated that the QuantiFERON-CMV assay is less sensitive than the ICS method for the detection of CMV-specific IFN-γ-producing CD8+ T-cell responses in the allo-SCT setting. Nevertheless, it allowed the estimation of the total and polyfunctional CMV-specific IFN-γ-producing CD8+ T-cell responses in specimens that tested positive by both methods.
-
Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8 + T-cell response in allogeneic stem cell transplant recipients
Clinical and Vaccine Immunology, 2012Co-Authors: María Ángeles Clari, Beatriz Munoz-cobo, Isabel Benet, Elisa Costa, María José Remigia, Dayana Bravo, Paula Amat, David NavarroAbstract:The performance of the QuantiFERON-cytomegalovirus (CMV) assay was compared to that of a flow cytometry intracellular cytokine staining (ICS) method for the detection of CMV-specific gamma interferon (IFN-γ)-producing CD8(+) T-cell responses in allogeneic stem cell transplant (allo-SCT) recipients and for estimations of their magnitude and functionality. A total of 90 whole-blood specimens from 23 allo-SCT recipients was analyzed by both methods. Overall, the percentage of specimens that yielded concordant results by both methods was 68.8% (κ = 0.691; 95% confidence interval [CI], 0.548 to 0.835), and the sensitivity of the QuantiFERON-CMV assay for the detection of positive IFN-γ T-cell responses (>0.2 IU/ml), taking the ICS method as the reference, was 76.3%. The magnitude of IFN-γ-producing CD8(+) T-cell responses to CMV-specific peptides measured with the QuantiFERON-CMV assay correlated significantly (σ = 0.695; P =
S M Arend - One of the best experts on this subject based on the ideXlab platform.
-
effect of tuberculin skin testing on a mycobacterium tuberculosis specific interferon γ assay
European Respiratory Journal, 2007Co-Authors: Eliane M S Leyten, Tom H. M. Ottenhoff, Corine Prins, Ailko W J Bossink, Steven F T Thijsen, J T Van Dissel, S M ArendAbstract:Recently, interferon-γ release assays (IGRA) for specific diagnosis of Mycobacterium tuberculosis infection have become available. In recent UK tuberculosis (TB) guidelines, it has been advised to screen for latent M. tuberculosis infection using the tuberculin skin test (TST), followed by IGRA if the TST is positive. Since TST can boost immune responses to tuberculin, the present authors evaluated whether TST administration affects the result of QuantiFERON®-TB Gold in-tube (QFT-GIT), a whole blood-based IGRA. QFT-GIT was performed on the day of TST administration and the day of reading in 15 TST-negative subjects, 46 TST-positive subjects with recent or remote exposure to M. tuberculosis and five cured TB patients. No systematic boosting of QFT-GIT responses from negative to positive was observed. Only in a few TST-positive persons did TST enhance pre-existing QFT-GIT responses. Screening for latent Mycobacterium tuberculosis infection using tuberculin skin testing followed by interferon-γ release assays on the day of reading is a reliable approach, as the specificity of QuantiFERON®-TB Gold in-tube is not affected by prior tuberculin skin test administration.
-
comparison of mantoux and QuantiFERON tb gold tests for diagnosis of latent tuberculosis infection in army personnel
Clinical and Vaccine Immunology, 2007Co-Authors: Willeke P J Franken, Corine Prins, Joost F Timmermans, Evertjan H J Slootman, Johan Dreverman, Hans Bruins, Jaap T Van Dissel, S M ArendAbstract:The tuberculin skin test (TST) was compared with QuantiFERON-TB Gold in-tube (QFT-GIT) test for the diagnosis of tuberculosis in non-Mycobacterium bovis BCG-vaccinated military personnel. Among subjects positive by TST, 44.4% of recruits were positive by QFT-GIT compared with 11.5% subjects tested after missions abroad, suggesting that most TST conversions in the latter group were caused by nontuberculous mycobacteria.
Yoshihiro Kobashi - One of the best experts on this subject based on the ideXlab platform.
-
indeterminate results of QuantiFERON tb 2g test performed in routine clinical practice
European Respiratory Journal, 2009Co-Authors: Yoshihiro Kobashi, Keiji Mouri, Yasushi Obase, Tadaaki Sugiu, Naoyuki MiyashitaAbstract:The present authors assessed risk factors that can promote indeterminate results of QuantiFERON TB-2G (QFT-2G; Cellestis Ltd, Carnegie, Australia) tests. The subjects were 704 patients with suspected tuberculosis (TB) and latent TB infection between January 2005 and December 2007. The QFT-2G test and the tuberculin skin test (TST) were performed for all subjects. If the results of the QFT-2G test were indeterminate, the test was repeated within 1 month. In total, 72 (10.2%) patients showed indeterminate results on the QFT-2G test. Indeterminate results were due to positive control failure in 68 (88.9%) patients and negative control failure in four patients. The results of the TST were negative for 64 patients showing indeterminate results, the remaining eight patients showed a positive response to the TST. Indeterminate results were significantly associated with elderly and immunocompromised patients. Lymphocytopaenia and hypoalbuminaemia were significantly associated with indeterminate laboratory findings. When the QFT-2G test was repeated for all patients showing indeterminate results, 12 (16.7%) patients demonstrated determinate results on the subsequent test. Indeterminate results of the QuantiFERON TB-2G test under routine clinical practice are not infrequent. When scoring QuantiFERON TB-2G test results for elderly and immunocompromised patients, one must be careful because the possibility of obtaining determinate results may be low even if the test is repeated.
-
clinical evaluation of QuantiFERON tb 2g test for immunocompromised patients
European Respiratory Journal, 2007Co-Authors: Yoshihiro Kobashi, Keiji Mouri, Yasushi Obase, Minoru Fukuda, Naoyuki MiyashitaAbstract:The usefulness of the tuberculin skin test (TST) and the QuantiFERON TB-2G (QFT-TB) test were compared in immunocompromised patients. The subjects consisted of 252 immunocompromised patients who were clinically suspected of tuberculosis (TB) infection between April 2005 and December 2006. Regarding the underlying diseases, 74 subjects had malignant diseases, 72 were undergoing immunosuppressive treatment, 52 had diabetes mellitus, 50 had chronic renal failure and four had HIV infection. While the positive rate of the QFT-TB test for the diagnosis of TB infection (TB disease or latent TB infection) was 78.1%, that of TST for TB infection was 50.0%. The QFT-TB test was significantly better than TST. However, 32 (13%) patients had an indeterminate QFT-TB result. Indeterminate findings were significantly more frequent in patients receiving immunosuppressive treatment (28%), especially with lymphocytopaenia in the peripheral blood, than in those who had other underlying diseases. While TST-positive and QFT-TB test-negative results were recognised in immunocompromised patients with bacille Calmette–Guerin vaccination or nontuberculous mycobacterial disease, TST-negative and QFT-TB test-positive results were recognised in immunocompromised patients with a past history of TB infection. It was concluded that the QuantiFERON TB-2G test is a more useful diagnostic method for tuberculosis infection than tuberculin skin test for immunocompromised patients suspected of tuberculosis disease. However, because the results of the QuantiFERON TB-2G test show an indeterminate response for patients receiving immunosuppressive treatment, especially for those with lymphocytopaenia due to severe underlying diseases, care must be taken in the interpretation of the QuantiFERON TB-2G test for these patients.
